Search

314 Result(s)
Sort by

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Animal Health Partnering

Animal Health Partnering

Description Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team